SLC5A2 and Hyperkalemia: Studies are also looking at potential synergistic properties of non-steroidal MRAs with SGLT2 inhibitors; in the FIDELIO-DKD trial, lower rates of hyperkalemia were observed in patients receiving SGLT2 inhibitors [136].